OncoMethylome Sciences Closes License Agreement With Veridex For Detection Of Prostate Cancer
OncoMethylome Sciences licenses molecular test based on DNA methylation
OncoMethylome Sciences, a company developing advanced molecular diagnostic solutions for individualized cancer treatment and early detection of cancer, announced a license agreement with Veridex LLC, a Johnson & Johnson company.
Under the agreement, Veridex receives an exclusive global license from OncoMethylome Sciences to molecular prostate cancer assays. In addition, both parties have agreed on a development program and an option to license additional assays in the prostate cancer field.
OncoMethylome Sciences will receive an upfront payment, R&D payments, technology milestone payments, several sales milestone payments and royalties on Veridex' sales of the assays. Financial details of the agreement have not been disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.